News Releases

Printer friendly version

Protox To Present Interim Prostate Cancer Data At AUA Conference

Vancouver, British Columbia, September 7, 2007 – Protox Therapeutics Inc. (TSX-V:PRX) today announced that interim data from the recently completed Phase 1 clinical study testing PRX302 in patients with locally recurrent prostate cancer following radiation failure will be presented at the American Urological Association (“AUA”) South Central Section Annual Meeting. The conference will take place at the Broadmoor Hotel in Colarado Springs, Colarado.

Scott Coffield, M.D., Principal Investigator from the lead site at Scott and White Memorial Hospital, will present the data on Friday, September 7, 2007. The presentation, entitled "Interim Results of a Phase 1 Clinical Study for the Transperineal Intraprostatic Administration of PRX302 (PSA-PAH1) in Patients with Locally Recurrent Prostate Cancer" indicates that PRX302 is safe and well tolerated in patients and that it shows encouraging signs of therapeutic activity.

PRX302 is rationally designed to kill prostate cancer and hyperplastic cells that over-produce the enzyme prostate specific antigen (PSA). Patient enrollment has been completed for this Phase 1 study and top-line results were released in July indicating that PRX302 is safe and well tolerated and that a maximum tolerated dose was not reached in the study while encouraging signs of therapeutic activity were observed. Plans are currently underway to commence a Phase 2 study before the end of the year.

About Protox
Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. The company currently has four programs in clinical development based on two distinct but complementary platforms, INxin™ and PORxin™. A Phase 2a clinical trial evaluating PRX321 (INxin) for the treatment of primary brain cancer has been completed and the product candidate has received Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a Phase 1 clinical trial evaluating PRX321 for the treatment of patients with renal cell carcinoma and non-small cell lung cancer has been completed.  Patient enrollment has been completed for a Phase 1 clinical trial evaluating PRX302 (PORxin) for the treatment of localized prostate cancer.  A Phase 1 clinical trial evaluating PRX302 for the treatment of benign prostatic hyperplasia (enlarged prostate) is ongoing.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox’ current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information contact:

James Beesley
Director, Investor Relations
Protox Therapeutics
604-688-0199
jbeesley@protoxtherapeutics.com

Michael Moore
Investor Relations
The Equicom Group
416-815-0700 x 241
mmoore@equicomgroup.com